Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS). Methods: This retrospective pharmacovigilance study used the US FDA FAERS database (2007–2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes. Results: From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC₀₂₅: 0.151, β_Coeff: 0.314), vomiting (IC₀₂₅: 0.334, β_Coeff: 0.495), and delayed gastric emptying (IC₀₂₅: 0.342, β_Coeff: 0.453). Exenatide was associated with pancreatitis (IC₀₂₅: 0.601, β_Coeff: 0.851) and death (ROR: 4.50, IC₀₂₅: 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs. Conclusions: Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety.

Background: Community pharmacies are health care facilities that allows the public access to their medications, counselling, and advice about their health. Community pharmacies play critical role in the health delivery systems of several countries especially in developing countries and serve as the first point of call for the treatment and management of many ailments, including malaria. The study therefore examined community pharmacies treatment practices of malaria and residents’ pattern of antimalarial drug use in Abura Community, in the Cape Coast Metropolis of the Central Region of Ghana. Methods: We conducted a community-based cross-sectional survey involving 301 study participants from the Abura Community (Cape Coast Metropolis). A structured questionnaire was used to collect information from the study participants using accidental sampling technique. Descriptive statistics was performed using SPSS version 23.0 and Microsoft Excel 2010. Results: The age range of our study was between 15 and 60 years. Females were the majority (52.5%). The self-reported use of unprescribed antimalarial drugs was 41%. The source of the drugs were mainly community pharmacies, licenced chemical shops, self-herbal preparations, and left-over antimalarial drugs. Conclusion: A high proportion of our study participants reported self-medication of non-prescribed antimalarial drugs. These antimalarials included both orthodox and herbal medications, which were sourced from outlets like community pharmacies, licenced chemical sellers, and home herbal preparations. There is the need to intensify monitoring, public health education on self-medication and the training of staff of community pharmacies to ensure effective treatment and management of malaria at the community level.